Article
Ustekinumab in Crohn’s disease: real-world outcomes and predictors of response
Author/s | Lorenzo González, Laura
Valdés Delgado, Teresa Vázquez Morón, Juan María Castro Laria, Luisa Leo Carnerero, Eduardo Maldonado Pérez, María Belén Sánchez Capilla, Damián Pallarés Manrique, Héctor Sáez Díaz, Antonia Argüelles Arias, Federico |
Department | Universidad de Sevilla. Departamento de Medicina |
Publication Date | 2022 |
Deposit Date | 2024-04-30 |
Published in |
|
Abstract | Background: ustekinumab is a monoclonal antibody that
inhibits interleukins IL-12 and IL-23, and is approved for the
treatment of Crohn’s disease (CD) and, more recently, also
ulcerative colitis (UC). The aim of this ... Background: ustekinumab is a monoclonal antibody that inhibits interleukins IL-12 and IL-23, and is approved for the treatment of Crohn’s disease (CD) and, more recently, also ulcerative colitis (UC). The aim of this study was to evaluate the effectiveness and safety of ustekinumab, as well as to identify possible predictive factors of response in a real-life setting. Methods: an observational, retrospective, multicenter study was carried out in 4 hospitals in Andalusia. Adult patients with a confirmed diagnosis of CD treated with ustekinum ab from 2017 to 2019 were included. Clinical response was analyzed at 3, 6 and 12 months of treatment. Clinical disease activity was assessed with the Harvey-Bradshaw index (HBI) and the Crohn’s Disease Activity Index (CDAI); biochemical response was assessed with lab parameters such as CRP and ESR. One-year ustekinumab drug-survival was analyzed. Results: a total of 98 patients were analyzed (mean age, 43 years; 52 % were male); 56 % had failed with ≥ 2 previous biologicals therapies. At 3 months, 69 % of the patients were in response and 40.8 % in remission. At 6 months, 56 % were in clinical remission. At 12 months, 73.7 % were in clinical response and 60.5 % in remission. Corticoste roid-free remission was 32.4 %, 44 %, and 47.4 % at 3, 6, and 12 months, respectively. Cumulative survival after one year of treatment with ustekinumab was 85.3 %. Biochemical parameters such as CRP and ESR showed a statistically significant decrease between baseline and control levels at 3, 6, and 12 months. A lower HBI at baseline and female sex were predictors of corticosteroid-free clinical remission in a univariate analysis. In the multivariate analysis no vari ables were found as predictors of corticosteroid-free clinical remission. Conclusion: ustekinumab therapy is safe and useful, induc ing clinical response in more than 50 % of patients, includ ing patients who failed with other biologica. |
Citation | Lorenzo González, L., Valdés Delgado, T., Vázquez Morón, J.M., Castro Laria, L., Leo Carnerero, E., Maldonado Pérez, M.B.,...,Argüelles Arias, F. (2022). Ustekinumab in Crohn’s disease: real-world outcomes and predictors of response. Revista Española de Enfermedades Digestivas, 114 (5), 272-279. https://doi.org/10.17235/reed.2020.7352/2020. |
Files | Size | Format | View | Description |
---|---|---|---|---|
Ustekinumab in Crohn’s.pdf | 900.3Kb | [PDF] | View/ | |